The main findings of our study investigating the use of P2Y12-inhibitors in a population of subjects with acute coronary syndrome undergoing invasive revascularization exhibited a clopidogrel use in 29.2% of our patients at admission and in 27.2% at hospital discharge. The gene discussed is P2RY12; the disease is acute coronary syndrome.